Modeling the population health impact of incorporating a multi-cancer early detection (MCED) test to existing cancer screening among immunocompromised individuals

References

• SEER*Explorer: An interactive website for SEER cancer statistics: Surveillance Research Program, National Cancer Institute. Available from: https://seer.cancer.gov/statistics-network/explorer/
   Google Scholar
• Schiffman JD, Fisher PG, Gibbs P. Early detection of cancer: past, present, and future. Am Soc Clin Oncol Educ Book. 2015:57-65.
   Google Scholar
• Siu AL, U. S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Feb 16;164(4):279-96.
   Google Scholar
• U. S. Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Aug 21;320(7):674-686.
   Google Scholar
• U. S. Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 May 18;325(19):1965-1977.
   Google Scholar
• U. S. Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Mar 9;325(10):962-970.
   Google Scholar
• U. S. Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 8;319(18):1901-1913.
   Google Scholar
• Cancer Facts & Figures 2022. Atlanta: American Cancer Society, Inc.; 2023.
   Google Scholar
• Kim A, Gitlin M, Fadli E, et al. Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008-2020. Prev Med Rep. 2022 Dec;30:102046.
   Google Scholar
• Ilham S, Willis C, Kim K, et al. Cancer incidence in immunocompromised patients: a single-center cohort study. BMC Cancer. 2023 Jan 9;23(1):33.
   Google Scholar
• Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018 Jan;68(1):31-54.
   Google Scholar
• Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Jun;31(6):745-759.
   Google Scholar
• Li B, Wang C, Xu J, et al. Abstract A06: Multiplatform analysis of early-stage cancer signatures in blood. Clinical Cancer Research. 2020;26(11_Supplement):A06-A06.
   Google Scholar
• Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019 Jun;570(7761):385-389.
   Google Scholar
• Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-1177.
   Google Scholar
• Hackshaw A, Cohen SS, Reichert H, et al. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer. 2021 Nov;125(10):1432-1442.
   Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007 May;117(5):1137-46.
   Google Scholar
• Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614.
   Google Scholar
• Complete Health Indicator Report of Cervical Cancer Screening (Pap): The Utah Cancer Control Program, Utah Department of Health and Human Services; 2022 [22 Oct 2022].
   Google Scholar
• Complete Health Indicator Report of Breast Cancer Screening (Mammography): The Utah Cancer Control Program, Utah Department of Health and Human Services; 2022 [22 Oct 2022].
   Google Scholar
• Health Indicator Report of Colorectal Cancer Screening: The Utah Cancer Control Program, Utah Department of Health and Human Services; 2022 [22 Oct 2022].
   Google Scholar
• State of Lung Cancer 2022: Utah: American Lung Association,; [22 Oct 2022]. Available from: https://www.lung.org/research/state-of-lung-cancer/states/utah
   Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-97.
   Google Scholar
• Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015 Apr 7;162(7):485-91.
   Google Scholar
• Kim JJ, Burger EA, Regan C, et al. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force. JAMA. 2018 Aug 21;320(7):706-714.
   Google Scholar
• Lehman CD, Arao RF, Sprague BL, et al. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology. 2017 Apr;283(1):49-58.
   Google Scholar
• Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. The Lancet. 2023;402(10409):1251-1260.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology 2022. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#detection
   Google Scholar
• Centers for Medicare & Medicaid Services. FY 2021 Final Rule and Correction Notice IPPS Impact File.
   Google Scholar
• Kreher MA, Noland MMB, Konda S, et al. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. Journal of the American Academy of Dermatology. 2023;88(3):521-530.
   Google Scholar
• Kreher MA, Noland MMB, Konda S, et al. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. J Am Acad Dermatol. 2023 Mar;88(3):521-530.
   Google Scholar
• State Cancer Profiles: National Cancer Institute; 2024 [2 Jun 2024]. Available from: https://statecancerprofiles.cancer.gov/incidencerates/index.php?stateFIPS=00&areatype=state&cancer=001&stage=999&race=00&sex=0&age=001&year=0&type=incd&sortVariableName=rate&sortOrder=desc
   Google Scholar
• Health Indicator Report of Physical Activity: Recommended Aerobic Activity Among Adults: Utah Department of Health and Human Services; 2022 [31 May 2024]. Available from: https://ibis.health.utah.gov/ibisph-view/indicator/view/PhysAct.html
   Google Scholar
• Health Indicator Report of Alcohol Consumption - Binge Drinking: Violence and Injury Prevention Program, Office of Health Promotion and Prevention, Utah Department of Health and Human Services; 2024 [31 May 2024]. Available from: https://ibis.health.utah.gov/ibisph-view/indicator/view/AlcConBinDri.html
   Google Scholar
• Health Indicator Report of Alcohol Consumption - Heavy Drinking: Violence and Injury Prevention Program, Office of Health Promotion and Prevention, Utah Department of Health and Human Services; 2024 [31 May 2024]. Available from: https://ibis.health.utah.gov/ibisph-view/indicator/view/AlcConChrDri.html
   Google Scholar
• Health Indicator Report of Smoking Among Adults: Tobacco Prevention and Control Program, Office of Health Promotion and Prevention, Utah Department of Health and Human Services; 2024 [31 May 2024]. Available from: https://ibis.health.utah.gov/ibisph-view/indicator/view/AlcConChrDri.html
   Google Scholar
• Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2020 Annual Data Report. 2022.
   Google Scholar
• Majhail NS, Tao L, Bredeson C, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501.
   Google Scholar
• Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007 Sep;27(5):497-502.
   Google Scholar
• Kobayashi RH, Litzman J, Rizvi S, et al. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. Immunotherapy. 2022 Mar;14(4):259-270.
   Google Scholar
• Kim A, Chung KC, Keir C, et al. Patient-reported outcomes associated with cancer screening: a systematic review. BMC Cancer. 2022 Mar 1;22(1):223.
   Google Scholar
• Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015 May;15(5):565-80.
   Google Scholar
• Health Indicator Report of Prostate Cancer Screening: The Utah Cancer Control Program, Utah Department of Health and Human Services; 2022 [22 Oct 2022].
   Google Scholar
• Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98.
   Google Scholar
• Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016 Jun 21;315(23):2576-94.
   Google Scholar
• Fedewa SA, Kazerooni EA, Studts JL, et al. State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States. J Natl Cancer Inst. 2021 Aug 2;113(8):1044-1052.
   Google Scholar